Isomorphic laboratories, the AI drug discovery platform that left Deepmind from Google in 2021, has raised external capital for the first time. The $ 600 million round was directed by Thrive Capital, with the participation of GV and the main alphabet of the existing investor of Google, said.
Financing will accelerate a greater development of the ISOMORPHIC AI DESIGN DESIGN MOTOR and support the company’s objective to bring their medicines discovered to clinical trials.
Isomorphic Labs was founded by the Deepmind co -founder, Demis Hassabis, taking advantage of the Deepmind software for the discovery of AI drugs, including Alfafold, an AI model that predicts the three -dimensional structures of proteins.
Last year, the isomorphic laboratories secured strategic associations with Eli Lilly and Novartis, which could generate up to $ 3 billion in payments for milestones for access to their AI model.
Hassabis said The New York Times Although isomorphic laboratories did not need the capital, additional financing will help the division to hire the main research scientists.
For their work in Alfafold, Hassabis and Deepmind researcher, John Jumper, were among the three scientists who received a Nobel Prize in Chemistry In 2024.
